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Lung fibroblasts are involved in airway inflammation and remodelling in COPD.
We report an investigation of the effects of combining a p38 MAPK inhibitor with
a corticosteroid on cytokine production by a human lung fibroblast cell line and
primary fibroblasts obtained from human lung tissue. Our main interest was to
determine whether additive or synergistic anti-inflammatory effects would be
observed. We observed inhibition of IL-6 and CXCL8 secretion from both lung
fibroblast models by dexamethasone (maximal inhibition 40–90%) and the p38
MAPK inhibitor BIRB (maximal inhibition 30–60%), used alone and evidence of
increased anti-inflammatory effects when used in combination. This combination
effect was more apparent for TNF-a stimulated cytokine production (maximal inhi-
bition increased by 10–20%). Interaction ratio analysis showed this enhanced
effect to be additive rather than synergistic interaction. Similar results were
obtained using both fibroblast cell culture models. Combining a p38 MAPK to cor-
ticosteroids may help reduce fibroblast mediated inflammation in COPD.
INTRODUCT ION
Fibroblasts are involved in airway remodelling in
chronic obstructive pulmonary disease (COPD) [1].
These cells regulate the structure of the extracellular
matrix (ECM) by secreting collagens, elastins and
matrix metalloproteinases, which contribute to ECM
turnover [2]. Fibroblasts also release pro-inflammatory
cytokines and chemokines which modify the activity of
other inflammatory cells. Fibroblasts from COPD
patients secrete higher levels of interleukin-6 (IL-6) and
C-X-C motif chemokine ligand 8 (CXCL8) compared to
healthy controls [3], which may contribute to the per-
sistent inflammation in COPD lungs.
Inhaled corticosteroids (ICS) are commonly used
anti-inflammatory drugs in COPD. Corticosteroids sup-
press the binding of transcription factors such as
nuclear factor-kappa B (NF-jB) to the promoter regions
of inflammatory genes [4]. However, many COPD
patients using ICS have persistent airway inflammation
[5,6] and continue to suffer with a heavy burden of
symptoms and exacerbations [7].
P38 mitogen-activated protein kinase (MAPK) acti-
vation increases the production of inflammatory media-
tors by enhancing gene transcription [8], mRNA
stability and protein translation [9,10]. Immunohisto-
chemical analysis has shown increased p38 MAPK
activation in the lungs of COPD patients [11,12]. In
vitro studies have demonstrated that p38 MAPK inhibi-
tors reduce cytokine production from various cell types
including alveolar macrophages, epithelial cells and
lung lymphocytes [11,13–15]. Furthermore, the combi-
nation of a p38 MAPK inhibitor with a corticosteroid
synergistically enhances inhibition of cytokine
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Société Française de Pharmacologie et de Thérapeutique.
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production from alveolar macrophages and bronchial
epithelial cells compared to corticosteroid alone
[15,16]. This may be related to phosphorylation of glu-
cocorticoid receptor (GR) by p38 MAPK; p38 MAPK
inhibition reduces phosphorylation of GR at serine
226, thereby increasing retention of GR in the nucleus
and enhancing GR activity [15,17]. Alternatively, cor-
ticosteroids increase the expression of phosphatases,
including mitogen-activated protein kinase phos-
phatase-1 (MKP-1) which downregulate p38 MAPK
activity [18].
The effects of p38 MAPK inhibitors vary between dif-
ferent cell types [13]. This paper reports an investiga-
tion of the effects of combining a p38 MAPK inhibitor
with a corticosteroid on cytokine production by pul-
monary fibroblasts. Our main interest was to determine
whether additive or synergistic anti-inflammatory
effects would be observed.
METHODS
Subjects
Four patients undergoing surgical resection for sus-
pected or confirmed lung cancer were recruited. There
were two males and two females and all patients were
smokers (3 current smokers and 1 ex-smoker) without
COPD (FEV1/FVC > 0.7). All subjects gave written
informed consent. The study was approved by the local
research ethics committee (South Manchester Research
Ethics Committee).
Primary human lung fibroblasts
Primary fibroblasts were isolated from resected lung tis-
sue using the outgrowth technique [19]. Briefly, lung
tissue was dissected into approximately 1mm3 pieces,
rinsed twice in DMEM supplemented with Glutamax
(Life Sciences), supplemented with 100 U/mL penicillin
and 100 nM streptomycin (Sigma, Poole, UK) and 10%
FCS (Life Sciences) and 3 pieces were placed into a
25 cm2 tissue culture flask and cultured in supple-
mented DMEM. Media was changed every 2–3 days
until cells were 80% confluent. Primary fibroblasts
were sub-cultured using 0.05% trypsin-EDTA (Invitro-
gen, Paisley, UK).
Normal human lung fibroblasts
Normal human lung fibroblasts (NHLF) were purchased
from Cambrex, UK. Fibroblasts were cultured in tissue
culture flasks containing supplemented DMEM and
media was changed every 2–3 days until cells were
80% confluent. Cells were sub-cultured using 0.05%
trypsin-EDTA. All experiments using NHLFs were car-
ried out in triplicate.
Fibroblast cell culture
Cytokine analysis
Fibroblasts (primary and NHLFs) were seeded into flat
bottomed 96 well plates at 25 9 105 cells per well and
grown until 80% confluent before serum starving over-
night. Cells were then pre-treated with dexamethasone
(0.01–1 000 nM) (Sigma), BIRB-796 (0.01–1 000 nM)
(Stratech Scientific Ltd, Newmarket, UK), or vehicle
control (dimethyl sulfoxide, Sigma) for one hour prior
to stimulation with IL-1b (10ng/ml, Peprotech, Lon-
don, UK) or tumour necrosis factor-a (TNF-a) (50 ng/
mL, Peprotech) for 24 h. In further experiments, each
dexamethasone concentration was used in combination
with each BIRB-796 concentration. Supernatants for
all experiments were harvested and stored at 80 °C.
All experiments were carried out in triplicate. Cell cul-
ture supernatants were analysed by enzyme-linked
immunosorbent assays (ELISA) according to manufac-
turers’ instructions (R&D Systems, Abingdon Oxford) to
quantify levels of CXCL8 and IL-6. Lower limits of
detection were 31.25 and 9.4 pg/mL respectively.
Western blot
NHLFs were seeded into flat bottomed 6 well plates at
1 9 106 cells per well and grown until 80% confluent
before serum starving overnight. Cells were then pre-
treated with dexamethasone (1 000 nM) or BIRB-796
(1 000 nM) for one hour prior to stimulation with
either IL-1b (10 ng/mL) or TNF-a (50 ng/mL) 0–
60 min. Following stimulation, supernatants were
removed and cells were rinsed with sterile PBS before
being isolated in radio immunoprecipitation assay
(RIPA) buffer (10 mM Tris-HCl, pH 7.4, 150 mM NaCl,
1 mM EDTA, 0.1% Nonidet P-40) containing phos-
phatase (Sigma Aldrich, Poole, Dorset, UK) and pro-
tease inhibitors (Calbiochem, San Diego, CA). The cell
suspension was then centrifuged at 400 g for 10 min
at 4 °C and protein quantification was performed on
the supernatant using the Bradford Assay (Sigma).
Samples were diluted to equal protein concentration in
sample buffer (62.5 mM Tris, 10% glycerol, 1% SDS,
1% b-mercaptoethanol and 0.01% bromphenol blue,
pH 6.8), boiled at 90 °C and stored at 80 °C for
western blot.
The following primary antibodies (from New England
Biolabs, Hitchen, UK, unless stated) were used: p38
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(#9212; recognizes p38a, -b, and -c), pp38 (#9211;
threonine 180 and tyrosine 182), GR (clone 41, Bec-
ton Dickinson UK, Oxford, UK) and pGR S211
(#4161).
Protein was electrophoresed on 10% SDS/acrylamide
gels before being transferred onto 0.2 µm nitrocellulose
membrane (BioRad, Hemel Hempstead, UK) for 1 h at
4 °C. Membranes were blocked for 1 h in blocking buf-
fer (5% milk in 19 TBS, 0.1% tween-20) before incu-
bating with primary antibody (diluted in block buffer)
over night at 4 °C. Membranes were washed for
2 9 5 min in wash buffer (88 mM Tris pH 7.8, 0.1%
Tween-20), prior to incubating with species-specific
horse radish peroxidise conjugated goat anti-rabbit sec-
ondary antibody (New England Biolabs) for 1 h at
room temperature. Membranes were washed
(3 9 5 min) in wash buffer and immunoreactive pro-
teins were visualized using enhanced chemilumines-
cence in the BioRad Universal Hood II with Quantity
One Software. Protein molecular weights were deter-
mined using Precision Plus Standards (BioRad).
Immunofluorescence
Primary fibroblasts were seeded into flat bottomed 8
well glass chamber slides at 25 9 105 cells per well
and grown 2–3 days until 80% confluent. Media was
removed and cells were washed in PBS before fixation
in 4% paraformaldehyde. Cells were blocked in 1.5%
heat inactivated normal serum (Vector Labs) then
labelled with the following primary antibodies over-
night at 4 °C: cytokeratin clone MNF116, alpha
smooth muscle actin clone 1AF or vimentin clone
Vim3B4 (all Dako). Primary antibodies were detected
using Alexa 488 conjugated secondary antibodies
(Invitrogen) and cells were counterstained with 40, 6-
diamidino-2-phenylindole (DAPI).
Statistics
Statistical analysis was performed using GraphPad
Instat (GraphPad Software Inc, La Jolla, California,
USA). Comparison of unstimulated to stimulated cells
was analysed by a one-way ANOVA followed by a Dun-
nett’s multiple comparisons test. Dexamethasone and
BIRB-796 concentration curves were compared to their
respective controls by a one-way ANOVA followed by a
Dunnett’s multiple comparison test. Comparison of dex-
amethasone and BIRB-796 concentration curves
between NHLFs and primary fibroblasts was analysed
by a two-way ANOVA followed by a Tukey’s multiple
comparisons test. Comparison of combined dexametha-
sone and BIRB-796 treatment to either compound
alone was analysed by a two-way ANOVA followed by
a Tukey’s multiple comparison test. Interaction ratios
were calculated from the ratio of observed efficacy (IO)
to expected efficacy (IE). The expected efficacy was cal-
culated using the Abbott formula: IE = A + B(AB/
100) where A is efficacy of compound A and B is effi-
cacy of compound B. An interaction ratio between 0.5
and 1.5 is consistent with an additive effect [20].
RESULTS
IL-1b and TNF-a stimulated CXCL8 and IL-6 release
from NHLFs and primary fibroblasts
NHLFs
In NHLFs, TNF-a significantly increased release of
CXCL8 and IL-6 (both P < 0.001) compared to basal
levels (Figure 1). Similarly, IL-1b significantly increased
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Figure 1 TNFa and IL-1b induced CXCL8 and IL-6 release from NHLFs and primary fibroblasts. NHLFs (n = 3) and primary human
fibroblasts (n = 4) were cultured with and without IL-1b and TNFa for 24 h and supernatants were collected and analysed for CXCL8 (a)
and IL-6 (b) release. Data shown are mean  SEM. * and *** = significant difference compared to untreated control where P < 0.05
and P < 0.001 respectively.
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CXCL8 and IL-6 (both P < 0.001) release compared to
basal levels (Figure 1). IL-1b stimulated significantly
higher levels of IL-6 release compared to TNF-a
(P < 0.001).
Primary fibroblasts
Primary fibroblast cultures were not contaminated with
epithelial cells; the cells were positive for the fibroblast
markers vimentin and a-smooth muscle actin and neg-
ative for the epithelial marker cytokeratin (Figure S1).
In primary fibroblasts, TNF-a significantly increased
secretion of CXCL8 and IL-6 compared to basal levels
(P = 0.03 and P = 0.04 respectively; Figure 1). Simi-
larly, IL-1b significantly increased CXCL8 and IL-6
release compared to basal levels (P = 0.04 and
P = 0.03 respectively). There was a trend towards sig-
nificantly higher IL-1b stimulated release of IL-6 com-
pared to TNF-a (P = 0.06).
TNF-a stimulated CXCL8 release from NHLFs was
significantly higher compared to primary fibroblasts
(P = 0.02; Figure 1). There was no significant differ-
ence in the levels of TNF-a stimulated IL-6 and IL-1b
stimulated CXCL8 and IL-6 when comparing NHLFs to
primary fibroblasts.
TNF-a and IL-1b stimulate phosphorylation of p38
MAPK in NHLFs
In NHLFs, TNF-a and IL-1b caused a time dependent
increase in the phosphorylation of p38-MAPK, return-
ing to basal levels by 60 min (Figure S2). Neither TNF-
a or IL-1b changed total p38-MAPK expression.
Dexamethasone (1 000 nM) caused a time dependant
increase in glucocorticoid receptor (GR) phosphoryla-
tion at serine 211 in NHLFs (Figure S2). Dexametha-
sone (1 000 nM) did not inhibit IL-1b or TNF-a
stimulated phosphorylation of p38 MAPK (Figure 2). In
contrast, BIRB-796 (1000nM) inhibited IL-1b and
TNF-a stimulated phosphorylation of p38 MAPK.
Dexamethasone inhibition of cytokine release
In NHLFs and primary fibroblasts, dexamethasone sig-
nificantly inhibited TNF-a and IL-1b stimulated CXCL8
and IL-6 release in a concentration dependant manner
(Figure 3 and Figure S3). Dexamethasone inhibition of
TNF-a stimulated CXCL8 (at 1 nM) and IL-1b stimu-
lated CXCL8 and IL-6 (at 0.1 and 1 nM) release was
significantly greater (P < 0.05) in NHLFs compared to
primary fibroblasts.
P38 MAPK inhibition of cytokine release
In NHLFs and primary fibroblasts, BIRB-796 inhibited
TNF-a and IL-1b stimulated CXCL8 and IL-6 release in
a concentration dependant manner (Figures 4 and S4).
However, in primary fibroblasts, the level of inhibition
did not reach statistical significance for TNF-a stimu-
lated CXCL8 release. There was no significant differ-
ence in the level of BIRB-796 inhibition when
comparing NHLFs to primary fibroblasts.
Combination Inhibition of cytokine release
In NHLFs and primary fibroblasts, the effects of combi-







































Figure 2 The effects of dexamethasone and BIRB-796 on phospho-p38 MAPK expression in NHLFs. NHLFs (n = 3) were pre-treated with
dexamethasone (1 000 nM) or BIRB-796 (1 000 nM) for 1 h prior to stimulation with TNF-a (a) or IL-1b (b) for 20 min. Cell lysates
were analysed for phospho-p38 MAPK, total p38,phosphor-GR (S211)and beta actin by western blot.
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treatment alone (Figures 5 and 6), although these dif-
ferences were more apparent for TNF-a stimulated
cytokines than IL-1b stimulated cytokines. Statistically
significant differences for combination treatment versus
one treatment were observed at a number of concen-
trations (see Table 1 for the highest drug concentra-
tions and Tables S1–S4 for complete listing of results).
For the majority of combinations, interaction ratios
ranged from 0.5 to 1.2 with none over 1.5, indicating
that increased inhibition by combining dexamethasone
with BIRB-796 was addition and not synergy.
DISCUSS ION
We have demonstrated inhibition of lung fibroblast
cytokine secretion by a corticosteroid or a p38 MAPK
inhibitor used alone, and increased anti-inflammatory
effects when used in combination. This combination
effect was more apparent for TNF-a stimulated cytokine
production. Interaction ratio analysis showed this
enhanced effect to be additive rather than synergistic
interaction.
A strength of this study is the use of two different
sources of lung fibroblasts; a cell line and fibroblasts
cultured directly from surgically resected lungs. We
observed similar results with both cell types concern-
ing additive combination effects. It has previously
been shown that increased p38 MAPK phosphoryla-
tion is associated with reduced sensitivity to corticos-
teroids [14,15,21]. We and others have shown that
p38 MAPK inhibition reduces phosphorylation of GR
at serine 226 [15,22]; phosphorylation at serine 226
causes GR to shuttle out of the nucleus, thereby
reducing GR activity [21,23]. By inhibiting p38
MAPK, GR remains in the nucleus for longer enabling
prolonged suppression of gene transcription [24]. This
is a molecular mechanism to explain the synergistic
effects of combined corticosteroid and p38 MAPK inhi-
bitor treatment [15,16]. We did not observe a syner-




Figure 3 Dexamethasone inhibition of TNF-a and IL-1b induced CXCL8 and IL-6 release from NHLFs and primary fibroblasts; per cent
inhibition. NHLFs (n = 3) and primary (n = 4) fibroblasts were pre-treated with dexamethasone (0.1–1000 nM) for 1 h prior to TNF-a (a
and c) or IL-1b (b and d) stimulation. Supernatants were analysed for CXCL8 (A and B) and IL-6 (c and d). Data shown are
mean  SEM. * and ** = significant difference between NHLFs and primary fibroblasts whereP < 0.05 and P < 0.01 respectively
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results suggest that useful additional anti-inflamma-
tory effects on lung fibroblasts can be obtained by
combining these two drug classes that act through
different mechanisms.
We observed greater additive effects in the TNF-a
stimulated compared to the IL-1b stimulated cellular
models. TNF-a and IL-1b production and signal trans-
duction are different processes. Following exposure to
pathogen-associated molecular patterns (PAMPs) or
danger-associated molecular patterns (DAMPs), de
novo synthesis of TNF-a occurs and membrane bound
TNF-a is cleaved by TNF-a converting enzyme (TACE)
to produce soluble TNF-a which activates TNF receptor
1 (TNFR1) or TNFR2 [25]. Conversely, IL-1b secretion
is a two part process: firstly, pro-IL-1b is produced in
response to an initial PAMP/DAMP signal, considered
a priming event. Upon exposure to a second signal,
pro-IL-1b is processed to its mature form by caspase-1
at the inflammasome and secreted to activate the IL-1
receptor/ IL-1 receptor accessory protein complex [26].
Both TNF-a and IL-1b signalling converge on similar
downstream effectors including NF-jB, activator pro-
tein-1 (AP-1) and p38 MAPK, to induce pro-inflamma-
tory gene transcription [25,26]. However, differences
in the downstream signalling cascade have been
observed, specifically TNF-a dependant activation of
interferon regulatory factor (IRF) 3 and IRF7 [27]. This
may reflect temporal differences in post-transcriptional
programs and sustained anti-viral responses which
contribute to higher levels of inflammatory cytokine
output.
Our results indicate that IL-1b signalling, compared
to TNF-a signalling, is more sensitive to corticosteroid
inhibition in human lung fibroblasts. This may be
related to differences in the signalling pathways out-
lined above. TNF-a is a pro-inflammatory cytokine
which amplifies the immune response and increases
leucocyte influx [28]. The levels of TNF-a are increased
in the airways of COPD patients compared to controls
and in the sputum of exacerbating COPD patients com-
pared to the stable state [29,30]. Bacterial endotoxin is
a potent stimuli of TNF-a from various cell types
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Figure 4 BIRB-796 inhibition of TNF-a and IL-1b induced CXCL8 and IL-6 release from NHLFs and primary fibroblasts; per cent
inhibition. NHLFs (n = 3) and primary fibroblasts (n = 4) were pre-treated with BIRB-796 (0.1–1000 nM) for 1 h prior to TNF-a (a and
c) or IL-1b (b and d) stimulation. Supernatants were analysed for CXCL8 (a and b) and IL-6 (c and d). Data shown are mean  SEM.
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including lung macrophages [31]. Increased levels of
TNF-a are increased in the airways of exacerbating
COPD patients colonized with Non typeable Haemophilus
influenza and Moraxella catarrhalis [32]. Bacterial colo-
nization of the airways is known to cause inflammation
and tissue remodelling in COPD patients [1,33,34], and
TNF-a appears to have a central role in these pro-
cesses. Our results suggest that combining a p38
MAPK inhibitor with a corticosteroid can be an effec-
tive anti-inflammatory strategy that targets TNF-a dri-
ven signalling pathways in human lung fibroblasts.
CXCL8 is a neutrophil chemokine that is less sensi-
tive to corticosteroid mediated inhibition compared to
other cytokines released from lung macrophages and
smooth muscle cells [35,36]. CXCL8 levels are
increased in the lungs of COPD patients [37,38].
Uncontrolled influx of neutrophils during chronic
inflammation can cause tissue damage due to the
release of proteases [39,40]. The addition of a p38
MAPK inhibitor to corticosteroid treatment may there-
fore enhance inhibition of CXCL8 production from vari-
ous cell types including fibroblasts, therefore limiting
the damage caused by neutrophil mediated inflamma-
tion [15–17].
It has previously been shown that the p38 MAPK
inhibitor SB203580 reduces bradykinin induced pro-
duction of IL-6 and CXCL8 from primary human lung
fibroblasts and IL-1b and TNF-a induced IL-6 and
CXCL8 from synovial fibroblasts [41,42]. However, sig-
nificant inhibition was only observed at high concen-
trations of compound (1–30 µM). We observed
inhibition at concentrations as low as 0.1 nM, using a
different p38 MAPK inhibitor. Although not studied
here, p38 MAPK inhibition reduces fibroblast prolifera-
tion and differentiation into myofibroblasts [43]. An
increase in fibroblast numbers and differentiation into
myofibroblasts can lead to scarring and fibrotic remod-
elling [1]. These findings may have implications for
fibrotic remodelling of the small airways, a common
feature in small airway disease in COPD [44].
We confirmed the identity of primary fibroblasts by
positive immunoreactivity for the fibroblast marker,
vimentin [45]. We also observed immunoreactivity for
a-smooth muscle actin, used to identify activated
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Figure 5 Combined dexamethasone and BIRB-796 inhibition of TNF-a and IL-1b induced CXCL8 and IL-6 from NHLFs. NHLFs (n = 3)
were pre-treated with dexamethasone (0.1–1 000 nM), or BIRB-796 (0.1–1 000 nM), in combination for 1 h prior to TNF-a (a and c) or
IL-1b (b and d) stimulation. Supernatants were analysed for CXCL8 (a and b) and IL-6 (c and d). Data shown are mean  SEM.
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fibroblasts or differentiation to myofibroblasts [45].
Samples were obtained from donors with a smoking
history and thus, previous smoke exposure may have
influenced the characteristics of the isolated fibroblasts;
cigarette smoke increases myofibroblast differentiation
[46,47]. However, we cannot rule out the impact of
culture conditions (e.g. time, cultureware) on the
expression of a-smooth muscle actin; cardiac fibroblasts
express lower levels of a-smooth muscle actin when
cultured on collagen coated pads compared to standard
cultureware [48]. Nevertheless, the use of activated
fibroblasts in our culture system is highly relevant as
this may better represent the status of these cells
in vivo.
Clinical trials using p38 MAPK inhibitors in COPD
patients have yielded mixed results [49–51]. However,
narrow spectrum p38 MAPK inhibitors and targeted
suppression of inflammation post exacerbation have



































































D ex + 10 0nM B IR B
D ex + 10 00 nM B IR B



























































Figure 6 Combined dexamethasone and BIRB-796 inhibition of TNF-a and IL-1b induced CXCL8 and IL-6 release from primary
fibroblasts. Primary fibroblasts (n = 4) were pre-treated with dexamethasone (0.1–1 000 nM), or BIRB-796 (0.1–1 000 nM), in
combination for 1 hour prior to TNF-a (a and c) or IL-1b (b and d) stimulation. Supernatants were analysed for CXCL8 (a and b) and IL-
6 (c and d). Data shown are mean  SEM.
Table 1 Per cent inhibition of TNF-a and IL-1b induced cytokine production from NHLFs and primary fibroblasts by dexamethasone and
BIRB-796 alone or in combination
TNF-a induced
CXCL8 IL-1b induced CXCL8 TNF-a induced IL-6 IL-1b induced IL-6
NHLF Primary NHLF Primary NHLF Primary NHLF Primary
Dex (1 000 nM) 61% 40% 72%*** 79%*** 57% 66%*** 91%** 92%***
BIRB (1 000 nM) 62% 42% 47% 38% 70% 37% 72% 52%
Dex (1 000 nM) + BIRB (100 nM) 78%† 61% 84%† ¶¶¶ 85%¶¶¶ 79% 76%¶¶¶ 91% ¶¶¶ 96%¶¶¶
IR 0.9 0.9 1.0 1.0 0.9 1.0 0.9 1.0
Data presented as means. *, **, *** = significantly above BIRB-796 (2-way ANOVA where P < 0.05, 0.01 and 0.001 respectively). † = significantly above dex-
amethasone (2-way ANOVA where P < 0.05). ¶¶¶ = significantly above BIRB-796 (2-way ANOVA where P < 0.001). Dex: dexamethasone; IR: interaction ratio.
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shown promise [52–54]. COPD exacerbations con-
tribute to inflammation and remodelling of small air-
ways in COPD patients. P38 MAPK inhibition may
therefore reduce pro-inflammatory and pro-fibrotic
effects of lung fibroblasts which contribute to small air-
way disease.
CONCLUS ION
In conclusion, we have demonstrated additional anti-
inflammatory effects when combining a p38 MAPK
inhibitor with a corticosteroid in human lung fibrob-
lasts. This may have implications for fibroblast medi-
ated inflammation and remodelling in COPD.
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